BioTime, Inc. (BTX)

1.23
AMEX
Prev Close 1.25
Day Low/High 1.21 / 1.25
52 Wk Low/High 0.66 / 2.61
Exchange AMEX
Shares Outstanding 149.36B
Market Cap 186.70M
Div & Yield N.A. (N.A)
First Week of July 17th Options Trading For BioTime (BTX)

First Week of July 17th Options Trading For BioTime (BTX)

Investors in BioTime, Inc. saw new options begin trading this week, for the July 17th expiration.

William Annett Named Chief Executive Officer Of OncoCyte Corporation

William Annett Named Chief Executive Officer Of OncoCyte Corporation

OncoCyte Corporation, a cancer diagnostics company and a member of the BioTime, Inc.

BioTime To Present At The Jefferies 2015 Global Healthcare Conference

BioTime To Present At The Jefferies 2015 Global Healthcare Conference

BioTime, Inc. (NYSE MKT: BTX) today announced that Chief Executive Officer Michael D.

OncoCyte's Collaborators At The Wistar Institute Present Positive Clinical Interim Results Of Blood-Based Diagnostic Test For Non-Invasive Detection Of Lung Cancer

OncoCyte's Collaborators At The Wistar Institute Present Positive Clinical Interim Results Of Blood-Based Diagnostic Test For Non-Invasive Detection Of Lung Cancer

BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced the presentation of positive interim clinical results demonstrating the high level of observed sensitivity and specificity in the assayed...

OncoCyte Corporation Completes Equity Financing Round

OncoCyte Corporation Completes Equity Financing Round

BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has received a new round of financing to fund further development and commercialization activities for its cancer diagnostic...

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel's Office Of The Chief Scientist

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel's Office Of The Chief Scientist

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd.

BioTime, Inc. Reports First Quarter 2015 Results And Recent Corporate Accomplishments

BioTime, Inc. Reports First Quarter 2015 Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT:BTX) today reported financial results for the first quarter ended March 31, 2015 and provided a corporate update.

Cell Cure Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen® Preserves Vision

Cell Cure Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen® Preserves Vision

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd.

BioTime's Clinical Grade Stem Cells From Subsidiary ES Cell International To Be Used In Planned CIRM-Funded Preclinical Studies Of Huntington's Disease

BioTime's Clinical Grade Stem Cells From Subsidiary ES Cell International To Be Used In Planned CIRM-Funded Preclinical Studies Of Huntington's Disease

BioTime, Inc. (NYSE MKT:BTX) today announced that the clinical-grade human Embryonic Stem (hES) cell lines from BioTime's wholly-owned subsidiary ES Cell International Pte Ltd (ESI, Singapore) will be used by UC Irvine...

BioTime Licenses Beckman Research Institute Of City Of Hope To Manufacture Clinical Grade Stem Cells

BioTime Licenses Beckman Research Institute Of City Of Hope To Manufacture Clinical Grade Stem Cells

BioTime, Inc. (NYSE MKT: BTX) today announced a nonexclusive License Agreement between BioTime's subsidiary ES Cell International Pte Ltd (ESI) and Beckman Research Institute of the City of Hope (BRICOH, Duarte, CA) through...

OncoCyte Announces Initial Data From Ongoing Clinical Study Of Collagen Type X As A Marker And Potential Diagnostic For Breast Cancer And Other Types Of Human Cancers

OncoCyte Announces Initial Data From Ongoing Clinical Study Of Collagen Type X As A Marker And Potential Diagnostic For Breast Cancer And Other Types Of Human Cancers

BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced initial data from a large, prospective clinical study that showed the potential of PanC-Dx™, OncoCyte's non-invasive diagnostic...

Positive Clinical Results Of OncoCyte's PanC-Dx™ Diagnostic Test Demonstrate High Level Of Sensitivity And Specificity In Non-Invasive Detection Of Bladder Cancer

Positive Clinical Results Of OncoCyte's PanC-Dx™ Diagnostic Test Demonstrate High Level Of Sensitivity And Specificity In Non-Invasive Detection Of Bladder Cancer

BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced positive clinical results of PanC-Dx™, OncoCyte's class of proprietary, non-invasive cancer diagnostic tests, in detecting the most...

Www.lifemap-solutions.com

Www.lifemap-solutions.com

LifeMap Solutions, an emerging digital therapeutics provider and subsidiary of BioTime, Inc.

OncoCyte Announces Availability Of Abstracts With New Clinical Data From Studies Of PanC-Dx™ Cancer Diagnostic In Bladder And Breast Cancer

OncoCyte Announces Availability Of Abstracts With New Clinical Data From Studies Of PanC-Dx™ Cancer Diagnostic In Bladder And Breast Cancer

BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced the online availability of abstracts providing human clinical data highlighting the potential of PanC-Dx™, OncoCyte's class of...

BioTime, Inc. Reports Fourth Quarter And Fiscal Year End 2014 Financial Results And Recent Corporate Accomplishments

BioTime, Inc. Reports Fourth Quarter And Fiscal Year End 2014 Financial Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT: BTX) today reported financial results for the quarter and year ended December 31, 2014, and highlighted its fourth quarter and recent corporate accomplishments.

Icahn School Of Medicine At Mount Sinai And LifeMap Solutions Launch Asthma Study For IPhone

Icahn School Of Medicine At Mount Sinai And LifeMap Solutions Launch Asthma Study For IPhone

The Icahn School of Medicine at Mount Sinai and LifeMap Solutions, a subsidiary of BioTime (NYSE MKT:BTX), today announced the launch of a large-scale medical research study that uses the new ResearchKit framework developed...

BioTime Announces First Patient Treated In Pivotal Clinical Trial Of Renevia™ For HIV-Associated Lipoatrophy

BioTime Announces First Patient Treated In Pivotal Clinical Trial Of Renevia™ For HIV-Associated Lipoatrophy

BioTime, Inc. (NYSE MKT: BTX) today announced that the first patient was successfully treated in the Company's pivotal clinical trial in Europe assessing the efficacy of Renevia™ for the treatment of HIV-associated...

Cell Cure Neurosciences Ltd. Provides Update On Its Product Development And Partnering Activities

Cell Cure Neurosciences Ltd. Provides Update On Its Product Development And Partnering Activities

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd.

OncoCyte To Present Cancer Diagnostic Clinical Study Data At AACR Annual Meeting

OncoCyte To Present Cancer Diagnostic Clinical Study Data At AACR Annual Meeting

BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that two abstracts, summarizing clinical studies of OncoCyte's PanC-Dx™ diagnostic products for bladder and breast cancer, have...

BioTime Announces Issuance Of 14 New Patents In The Fields Of Regenerative Medicine, Stem Cell Technology, And Cancer Therapy

BioTime Announces Issuance Of 14 New Patents In The Fields Of Regenerative Medicine, Stem Cell Technology, And Cancer Therapy

BioTime, Inc. (NYSE MKT: BTX) announced today the issuance of 14 new patents covering a wide range of the core technologies of BioTime and its subsidiaries Asterias Biotherapeutics, Inc.

BioTime Subsidiary OncoCyte Corporation Appoints William Annett To Its Board Of Directors

BioTime Subsidiary OncoCyte Corporation Appoints William Annett To Its Board Of Directors

BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that William Annett has been appointed to OncoCyte's Board of Directors.

BioTime Appoints Adi Mohanty Chief Operating Officer

BioTime Appoints Adi Mohanty Chief Operating Officer

BioTime, Inc. (NYSE MKT:BTX), a leader in developing pluripotent stem-cell therapies and other technologies designed to address major unmet medical needs, today announced the appointment of Adi Mohanty to the position of...

BioTime Subsidiary ES Cell International And GE Healthcare Cross-License Patents In The Field Of Cell Assays For Drug Testing

BioTime Subsidiary ES Cell International And GE Healthcare Cross-License Patents In The Field Of Cell Assays For Drug Testing

BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary ES Cell International Pte.

BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment Of Clinical Study Of Urine-Based Bladder Cancer Diagnostic

BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment Of Clinical Study Of Urine-Based Bladder Cancer Diagnostic

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has completed enrollment in the initial clinical study of its urine-based bladder cancer diagnostic test.

BioTime Appoints Angus C. Russell To Board Of Directors

BioTime Appoints Angus C. Russell To Board Of Directors

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Angus C.

BioTime To Host Investor And Analyst Day On December 15, 2014

BioTime To Host Investor And Analyst Day On December 15, 2014

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced today that it will host its Investor and Analyst Day meeting on Monday, December 15,...

Commit To Purchase BioTime At $2.50, Earn 14.5% Annualized Using Options

Commit To Purchase BioTime At $2.50, Earn 14.5% Annualized Using Options

Investors considering a purchase of BioTime, Inc. shares, but tentative about paying the going market price of $3.26/share, might benefit from considering selling puts among the alternative strategies at their disposal.

BioTime To Present At The LD Micro VII Conference

BioTime To Present At The LD Micro VII Conference

BioTime, Inc. (NYSE MKT:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D.

BioTime Reports Third Quarter Results And Recent Progress

BioTime Reports Third Quarter Results And Recent Progress

BioTime, Inc. (NYSE MKT: BTX), the leader in developing pluripotent stem-cell therapies and other technologies designed to address major unmet medical needs, today reported financial results for the third quarter and...

BioTime Receives Authorization To Begin Pivotal Human Clinical Trial Of Renevia™ In Europe

BioTime Receives Authorization To Begin Pivotal Human Clinical Trial Of Renevia™ In Europe

BioTime, Inc. (NYSE MKT:BTX) today reported that it has received authorization to begin its pivotal human clinical trial of Renevia™ in Europe.

TheStreet Quant Rating: D (Sell)